Profile data is unavailable for this security.
About the company
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
- Revenue in USD (TTM)9.29bn
- Net income in USD2.52bn
- Incorporated2012
- Employees13.80k
- LocationZoetis Inc10 Sylvan WayPARSIPPANY 07054United StatesUSA
- Phone+1 (973) 822-7000
- Fax+1 (302) 655-5049
- Websitehttps://www.zoetis.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. | 2.35bn | -269.70m | 41.06bn | 2.23k | -- | 355.53 | -- | 17.49 | -2.09 | -2.09 | 18.27 | 0.8858 | 0.5842 | 4.12 | 9.70 | 1,052,959.00 | -6.71 | -20.07 | -8.96 | -25.51 | 86.01 | 84.18 | -11.49 | -55.19 | 2.98 | -0.4627 | 0.8988 | -- | 22.97 | 59.21 | 36.82 | -- | -24.55 | -- |
| Regeneron Pharmaceuticals Inc | 14.09bn | 4.50bn | 61.30bn | 15.11k | 14.45 | 2.09 | 12.27 | 4.35 | 39.30 | 39.30 | 123.45 | 271.60 | 0.3917 | 0.6347 | 2.61 | 932,457.30 | 12.51 | 18.52 | 13.89 | 21.13 | 86.69 | 87.22 | 31.94 | 37.92 | 4.03 | -- | 0.0843 | -- | 8.27 | 12.55 | 11.61 | 15.84 | 15.46 | -- |
| Zoetis Inc | 9.29bn | 2.52bn | 68.99bn | 13.80k | 27.83 | 14.85 | 22.86 | 7.43 | 5.57 | 5.57 | 20.54 | 10.44 | 0.6529 | 1.07 | 7.00 | 672,898.60 | 17.77 | 15.25 | 21.83 | 18.31 | 70.98 | 70.18 | 27.22 | 26.32 | 1.04 | 21.14 | 0.5856 | 28.93 | 8.33 | 8.14 | 6.06 | 10.63 | 7.32 | 21.37 |
| Bristol-Myers Squibb Co | 47.64bn | 5.42bn | 95.36bn | 34.10k | 17.59 | 5.48 | 7.06 | 2.00 | 2.66 | 2.66 | 23.44 | 8.54 | 0.4976 | 4.27 | 5.12 | 1,396,950.00 | 5.68 | 0.6536 | 7.69 | 0.8175 | 74.69 | 76.63 | 11.41 | 1.52 | 1.17 | 7.39 | 0.7402 | 678.24 | 7.32 | 13.06 | -211.50 | -- | 8.34 | 7.91 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 39.43m | 8.81% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 23.15m | 5.17% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 19.80m | 4.42% |
| State Farm Investment Management Corp.as of 31 Mar 2025 | 15.89m | 3.55% |
| Geode Capital Management LLCas of 31 Mar 2025 | 10.99m | 2.45% |
| AllianceBernstein LPas of 31 Mar 2025 | 10.86m | 2.42% |
| Polen Capital Management LLCas of 31 Mar 2025 | 8.80m | 1.96% |
| Wellington Management Co. LLPas of 31 Mar 2025 | 6.01m | 1.34% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2025 | 5.50m | 1.23% |
| BlackRock Advisors (UK) Ltd.as of 31 Mar 2025 | 5.42m | 1.21% |
